Repeated i.v. injection of mouse Pah (MmPah) mRNA formulated in LNPs into a PKU (Pahenu2) mouse model resulted in therapeutic PAH protein production in the liver, decreased Phe concentrations in the serum, liver, and brain, and reversed disease progression [59]. The gene discussed is PAH; the disease is pulmonary arterial hypertension.